Jacob Mathew

Learn More
BACKGROUND Bladder cancer is one of the most common cancers in Europe, the United States, and Northern African countries. Muscle-invasive bladder cancer is an aggressive epithelial tumor, with a high rate of early systemic dissemination. Superficial, noninvasive bladder cancer can most often be cured; a good proportion of invasive cases can also be cured by(More)
Attachment-retained removable partial denture (RPD) is not an outdated treatment modality. It is even more contemporary in today’s appearance-oriented society than when it was first introduced. There is significant number of patients who could benefit from this treatment option, both short and long term. However, lack of proper knowledge, overwhelming(More)
The 3rd Breast-Gynecological International Cancer Conference, supported by the European Society of Medical Oncology (ESMO), was held in Cairo (Egypt) on 13-14 January 2011. The meeting was conducted under the patronage of Egypt's Ministry of Health, with the scientific committee led by Heba El Zawahry from the National Cancer Institute (Cairo, Egypt), and(More)
This research seeks to generate temporal event predictions using the sticky Hierarchical Dirichlet Process Hidden Markov Model (sticky HDP-HMM) [2], a generalization of the infinite HMM [1]. Hidden Markov Models (HMMs) are one of the most widely used machine learning techniques for analyzing temporal data. One significant limitation of this traditional(More)
One of the most rapidly growing areas of dentistry of both interest and need is maxillofacial prosthetics. Malignant tumours of the upper gum and hard palate account for 1-5% of malignant neoplasms of the oral cavity; two thirds of the lesions which involve these areas are squamous cell carcinomas. Most of these carcinomas are diagnosed late, when they(More)
PURPOSE OF REVIEW In this review, we aim to update the clinical data of trastuzumab-DM1 (T-DM1) in terms of safety and efficacy, and describe ongoing and future trials evaluating its potential role in the management of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. RECENT FINDINGS Trastuzumab emtansine (T-DM1) is an(More)
  • 1